BOSTON, MA - January 28, 2014 (Investorideas.com Newswire) SoundView Technology Group: NXT-ID (OTCQB: NXTD) www.nxt-id.com has effectively raised an additional round of capital that will come in two tranches -- $1.35M less expenses up front and another $4.4M from likely warrant exercises. The proceeds will aid the company in further development and the commercial launch of their innovative digital wallet (The Wocket www.thewocket.com).

In an unusually shareholder-friendly move founding members of the management team elected to surrender shares to offset the additional shares need for new investment capital. Few, if any, company managements go to such lengths to put shareholders first.

 New York, N.Y. - January 24, 2014 (www.investorideas.com newswire) Defense and Security News alert- Investorideas.com, an investor research and news portal covering leading sectors including technology and defense, announces new speakers for its upcoming Security and Defense Conference,” Game Changing Technologies: The Face and Future of Security”, to be held live in New York and online at Scribblelive.com on March 11, 2014.

Added to the growing list of speakers and presenters is Kris Tuttle Director of Research for SoundView Technology Group, cybersecurity expert and counterterrorism analyst Roger Cressey, Partner with Liberty Group Ventures and Kiersten Todt , President and Managing Partner of Liberty Group Ventures.

HomeTrust Bancshares, Inc. to Acquire Jefferson Bancshares, Inc. and Expand Into East Tennessee

HomeTrust Bancshares, Inc. ("HomeTrust") (HTBI) and Jefferson Bancshares, Inc. ("Jefferson") (JFBI) jointly announced today the signing of a definitive agreement under which HomeTrust will acquire Jefferson. Upon the completion of the transaction, the combined company is expected to have approximately $2.1 billion in assets.

Dana Stonestreet, Chairman, President, and CEO of HomeTrust said, "We are enthusiastic to enter the east Tennessee market by connecting with an institution sharing our core values. Both banking organizations are dedicated to providing superior customer service, placing value on their employees, and focusing continually on creating shareholder value.

 Montreal, Quebec, Canada - January 22, 2014 (Investorideas.com Biotech Newswire) Biopharma alert: Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, reports that it is targeting pancreatic cancer as a second indication for Adva-27a, the Company’s flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.